KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $7.5 billion.

  • Charles River Laboratories International's Liabilities and Shareholders Equity fell 6.12% to $7.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $30.2 billion, marking a year-over-year decrease of 6.55%. This contributed to the annual value of $7.5 billion for FY2024, which is 8.13% down from last year.
  • As of Q3 2025, Charles River Laboratories International's Liabilities and Shareholders Equity stood at $7.5 billion, which was down 0.62% from $7.6 billion recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Liabilities and Shareholders Equity ranged from a high of $8.2 billion in Q4 2023 and a low of $5.8 billion during Q1 2021.
  • Its 3-year average for Liabilities and Shareholders Equity is $7.8 billion, with a median of $7.7 billion in 2023.
  • As far as peak fluctuations go, Charles River Laboratories International's Liabilities and Shareholders Equity spiked by 35.39% in 2021, and later decreased by 8.13% in 2024.
  • Quarterly analysis of 5 years shows Charles River Laboratories International's Liabilities and Shareholders Equity stood at $7.0 billion in 2021, then climbed by 8.24% to $7.6 billion in 2022, then grew by 7.79% to $8.2 billion in 2023, then declined by 8.13% to $7.5 billion in 2024, then decreased by 6.12% to $7.5 billion in 2025.
  • Its Liabilities and Shareholders Equity was $7.5 billion in Q3 2025, compared to $7.6 billion in Q2 2025 and $7.6 billion in Q1 2025.